BiotechTube

KYV-101 anti-CD19 CAR-T cell therapy + Standard lymphodepletion regimen

Phase 1/2Active
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Lupus Nephritis

Conditions

Lupus Nephritis, Lupus Nephritis - World Health Organization (WHO) Class III, Lupus Nephritis - WHO Class IV

Trial Timeline

Apr 28, 2023 → Aug 1, 2027

NCT ID
NCT05938725

About KYV-101 anti-CD19 CAR-T cell therapy + Standard lymphodepletion regimen

KYV-101 anti-CD19 CAR-T cell therapy + Standard lymphodepletion regimen is a phase 1/2 stage product being developed by Kyverna Therapeutics for Lupus Nephritis. The current trial status is active. This product is registered under clinical trial identifier NCT05938725. Target conditions include Lupus Nephritis, Lupus Nephritis - World Health Organization (WHO) Class III, Lupus Nephritis - WHO Class IV.

Hype Score Breakdown

Clinical
13
Activity
8
Company
2
Novelty
4
Community
3

Clinical Trials (3)

NCT IDPhaseStatus
NCT06138132Phase 1Recruiting
NCT05938725Phase 1/2Active
NCT06342960Phase 1/2Active

Competing Products

20 competing products in Lupus Nephritis

See all competitors
ProductCompanyStageHype Score
Tabalumab Auto-Injector + Tabalumab Prefilled SyringeEli LillyPhase 3
77
Baricitinib + PlaceboEli LillyPhase 2
52
DS-7011a + PlaceboDaiichi SankyoPhase 1
33
DS-7011a + PlaceboDaiichi SankyoPhase 1/2
41
tacrolimusAstellas PharmaPhase 3
77
TacrolimusAstellas PharmaPre-clinical
23
tacrolimus capsule + tacrolimus placebo + leflunomide tablet + leflunomide placebo + prednisoneAstellas PharmaPhase 3
77
tacrolimusAstellas PharmaApproved
85
Tacrolimus capsules + Cyclophosphamide injections + PrednisoneAstellas PharmaPhase 3
77
E6742EisaiPhase 1/2
41
Baricitinib + PlaceboEli LillyPhase 3
77
Baricitinib + PlaceboEli LillyPhase 3
77
LY2127399 + Placebo every 2 weeks + Placebo every 4 weeks + Standard of CareEli LillyPhase 3
77
LY3361237 + PlaceboEli LillyPhase 2
52
LY2127399 + PlaceboEli LillyPhase 3
77
LY3361237 + PlaceboEli LillyPhase 1
33
LY2127399 + Placebo every 2 weeks + Placebo every 4 weeksEli LillyPhase 3
77
Baricitinib + PlaceboEli LillyPhase 3
77
LY3471851 + PlaceboEli LillyPhase 1
33
LY3471851 + PlaceboEli LillyPhase 2
52

Other Products from Kyverna Therapeutics

Standard of Care Treatment + Standard lymphodepletion regimen + KYV-101Phase 2/3
57
Standard lymphodepletion regimenPhase 2
44
KYV-101 + Standard lymphodepletion regimen + Anti-CD20 mABPhase 2
44
KYV-101, an autologous fully-human anti-CD19 CAR T-cell immunotherapyPhase 1/2
33
KYV-101 + Standard lymphodepletion regimenPhase 1/2
33